Hussman Strategic Advisors Inc. Takes Position in ANI Pharmaceuticals, Inc. $ANIP

Key Points

• Hussman Strategic Advisors bought a new stake of 31,500 shares in ANI Pharmaceuticals in Q4 (≈$2.49M), and other institutions including Arrowstreet, Balyasny and UBS also added large positions, leaving 76.05% institutional ownership.
• ANIP trades around $80 with a market cap of ~$1.8B and a P/E near 24; Wall Street's consensus is a Moderate Buy with an average price target of $107.33 (Guggenheim $124), while insiders have sold about 27,860 shares (~$2.11M) in the past 90 days and now own 8.10%.

Hussman Strategic Advisors Inc. purchased a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 31,500 shares of the specialty pharmaceutical company's stock, valued at approximately $2,487,000. Hussman Strategic Advisors Inc. owned 0.14% of ANI Pharmaceuticals at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in ANIP. Arrowstreet Capital Limited Partnership acquired a new stake in shares of ANI Pharmaceuticals in the third quarter valued at about $32,992,000. Balyasny Asset Management L.P. increased its stake in shares of ANI Pharmaceuticals by 2,785.7% in the third quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company's stock valued at $26,211,000 after buying an additional 276,233 shares during the period. Divisadero Street Capital Management LP acquired a new stake in shares of ANI Pharmaceuticals in the third quarter valued at about $21,454,000. Rubric Capital Management LP grew its stake in ANI Pharmaceuticals by 354.7% during the second quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company's stock worth $16,813,000 after purchasing an additional 200,998 shares during the period. Finally, UBS Group AG grew its stake in ANI Pharmaceuticals by 45.8% during the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company's stock worth $54,032,000 after purchasing an additional 185,172 shares during the period. Institutional investors and hedge funds own 76.05% of the company's stock.

ANI Pharmaceuticals Trading Up 1.2%

NASDAQ ANIP opened at $80.39 on Friday. The business has a 50 day simple moving average of $76.36 and a 200 day simple moving average of $81.24. ANI Pharmaceuticals, Inc. has a one year low of $56.71 and a one year high of $99.50. The stock has a market capitalization of $1.80 billion, a P/E ratio of 23.93 and a beta of 0.46. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.71 and a quick ratio of 2.19.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, insider Christopher Mutz sold 3,162 shares of the firm's stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $71.64, for a total value of $226,525.68. Following the completion of the sale, the insider owned 91,309 shares of the company's stock, valued at approximately $6,541,376.76. This trade represents a 3.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Meredith Cook sold 500 shares of the firm's stock in a transaction that occurred on Monday, April 13th. The shares were sold at an average price of $77.95, for a total value of $38,975.00. Following the completion of the sale, the vice president directly owned 78,890 shares of the company's stock, valued at $6,149,475.50. This trade represents a 0.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 27,860 shares of company stock valued at $2,111,581. Company insiders own 8.10% of the company's stock.

Wall Street Analyst Weigh In

ANIP has been the subject of several recent analyst reports. Zacks Research raised ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, April 15th. Guggenheim raised their target price on ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a "buy" rating in a research note on Friday, January 16th. Finally, Wall Street Zen cut ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, March 14th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $107.33.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.